The Sleeping-Beauty Transposase System, consisting of a transposase and a transposon, enables cost-effective, simple and highly efficient gene transfer. It offers an attractive alternative to viral gene transfer systems, because it significantly reduces the risks of immunogenicity or insertional mutagenesis and facilitates GMP compliance. Several…
Bureaucratic and institutional hurdles often complicate the foundation of spin-offs from research institutes. TransferAllianz, the German association for knowledge and technology transfer, has formulated clear, standardized cornerstones for academic spin-offs in the life sciences. The recommendations are aligned with the existing conditions of…
Aignostics, a global artificial intelligence (AI) company that turns complex multi-modal pathology data into transformative insights, has raised $34 million in Series B financing. The oversubscribed funding round was led by ATHOS, with investments from Mayo Clinic and growth financing from HTGF, alongside support from existing investors. As…
In his last position as investment analyst at Earlybird Health Venture Capital, Alejandro conducted due diligence on new business opportunities and sourced deals in the life science sector. Before, he was a postdoctoral researcher at the Max Planck Institute for Multidisciplinary Sciences Göttingen, advising the Neurogenetics Department on the…
Early this year we experienced an exceptional event in the German start-up scene, with Cardior’s billion-euro exit. Success stories like these motivate the Hannover Medical School (MHH) and other research institutes to carry on patenting good ideas and supporting inventors, entrepreneurs and their spin-offs – because the institutes participate…
Lead investor is Caesar Ventures, and co-investors include BIF Partners, another.vc and the MPF Accelerator. Lucid Genomic’s platform builds on research by Martin Vingron, Director of the Max Planck Institute for Molecular Genetics, and Stefan Mundlos, Director of the Institute of Medical Genetics and Human Genetics at the Charité –…
Allogenetics, a spin-off from Medical School Hannover (MHH) pioneers a new approach to solving the problem of transplant rejection. Although clinical outcomes have steadily improved, the life span of transplants remains unsatisfying, particularly with lungs. Around 50% of patients lose their allograft within 5 years. While current treatments focus…
PROTON builds on groundbreaking work of Prof. Mark Brönstrup and his team at the Helmholtz Center for Infection Research (HZI) on virulence mechanisms of Staphylococcus aureus, which causes a wide variety of clinical diseases. Their goal is to disarm the bacteria by blocking their toxins rather than killing them, which is becoming increasingly…
Knowledge and technology transfer
Broad engagement
As accredited coaches, consultants, trainers and experts, Ascenion’s employees contribute continuously to the development of the technology transfer landscape. We are involved – often in a voluntary capacity – in education and training, establishing professional standards and promoting of…
Dr Ralf Kühn, head of the Genome Engineering & Disease Models research group at the Max Delbrück Center, has been researching gene editing techniques for more than 10 years. His team uses and improves the CRISPR-Cas9 gene scissors. The HIROS/replace technology (Homology Independent Replacement of Sequences) developed in his laboratory and…
In his AnoxyGen project, Christian Hertweck is investigating the unique biosynthetic pathways and active compounds of anaerobic bacteria in order to better understand their role in nature and develop them for medical, ecological and biotechnological applications. Some of these applications could benefit humans, animals and the environment. Long…
The latest financing round is led by Vesalius Biocapital IV, with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF) and the High-Tech Gründerfonds (HTGF). The company is developing a new regenerative therapeutic concept for the treatment of acute and chronic liver diseases. The inhibitor HRX-215 supports,…
Privacy Policy for the Ascenion GmbH Website
1. Name and contact details of the controller This data protection information applies to data processing by: Controller:
Ascenion GmbH (hereinafter: Ascenion) Herzogstraße 64D-80803 Munich Munich, Germany E-mail: info(at)ascenion(dot)de Phone: +49 (0)89 - 318814-0 Fax: +49 (0)89 -…
